A Study Evaluating the Efficacy and Safety of Obinutuzumab in Participants With Primary Membranous Nephropathy

NCT04629248 · clinicaltrials.gov ↗

PHASE3

Phase

ACTIVE_NOT_RECRUITING

Status

142

Enrollment

INDUSTRY

Sponsor class

Conditions

Primary Membranous Nephropathy

Interventions

DRUG: Obinutuzumab
DRUG: Tacrolimus
DRUG: Methylprednisolone
DRUG: Acetaminophen
DRUG: Diphenhydramine

Sponsor

Hoffmann-La Roche